Y Intercept Hong Kong Ltd Invests $1.95 Million in Janux Therapeutics, Inc. $JANX

Y Intercept Hong Kong Ltd purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 139,967 shares of the company’s stock, valued at approximately $1,946,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JANX. Janus Henderson Group PLC increased its stake in Janux Therapeutics by 13.8% during the 4th quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock worth $73,850,000 after buying an additional 649,341 shares in the last quarter. State Street Corp raised its holdings in shares of Janux Therapeutics by 103.8% during the fourth quarter. State Street Corp now owns 3,853,951 shares of the company’s stock valued at $53,185,000 after acquiring an additional 1,962,486 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock valued at $59,074,000 after acquiring an additional 227,676 shares in the last quarter. Prosight Management LP lifted its position in shares of Janux Therapeutics by 176.5% in the fourth quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock valued at $33,017,000 after acquiring an additional 1,527,173 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its position in shares of Janux Therapeutics by 10.7% in the fourth quarter. Orbimed Advisors LLC now owns 1,954,426 shares of the company’s stock valued at $26,971,000 after acquiring an additional 188,326 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on JANX. Truist Financial reiterated a “buy” rating and set a $26.00 price target (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. JonesTrading lowered their target price on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. Piper Sandler reduced their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Weiss Ratings raised shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $40.15.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock opened at $16.66 on Thursday. The business’s 50 day moving average price is $14.41 and its 200 day moving average price is $14.16. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -9.05 and a beta of 2.52. Janux Therapeutics, Inc. has a one year low of $12.12 and a one year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. On average, analysts predict that Janux Therapeutics, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at $1,065,452.23. The trade was a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the completion of the transaction, the vice president owned 32,270 shares in the company, valued at $457,265.90. The trade was a 5.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.90% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.